Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, Investor Relations Ryan Spencer - Chief Executive Officer Donn Casale - Senior Vice President, Commercial Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Phil Nadeau - Cowen Ed White - H.C. Wainwright Matt Phipps - William Blair Operator Good day, ladies and gentlemen, and welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or other juris ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Kelly MacDonald - CFO Robert Janssen - CMO Donn Casale - SVP, Commercial Conference Call Participants Matt Phipps - William Blair Phil Nadeau - Cowen and Company Robert Palermo - Goldman Sachs & Co. LLC Josh Schimmer - Evercore ISI Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Tec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2021 Results Conference Call August 5, 2021 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Kelly MacDonald - CFO Robert Janssen - CMO Donn Casale - SVP, Commercial. Conference Call Participants Phil Nadeau - Cowen and Company Matt Phipps - William Blair Josh Schimmer - Evicore Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Second Quarter 2021 Conference Call. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or ot ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2021 Earnings Conference Call May 6, 2021 4:30 AM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Kelly MacDonald - CFO Rob Janssen - CMO Donn Casale - SVP, Commercial. Conference Call Participants Matt Phipps - William Blair Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies First Quarter 2021 Conference Call. As a reminder, this conference call is being recorded. At the end of the Company’s prepare ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or o ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2020 Results Conference Call February 25, 2021 4:30 AM ET Company Participants Nicole Arndt - Senior Manager, Investor Relations Ryan Spencer - Chief Executive Officer Michael Ostrach - Chief Financial Officer Rob Janssen - Chief Medical Officer Donn Casale - Vice President, Commercial Conference Call Participants Matt Phipps - William Blair & Company Edward White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technolog ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or other juris ...